Who are Provigil's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Pramipexole (Mirapex), Adjunctive asenapine, LYBALVI, Aripiprazole Augmentation, Quetiapine and Topiramate, Continuous Subcutaneous Lisuride Infusion.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/modafinil.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Provigil — Competitive Intelligence Brief

Provigil (modafinil) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Sympathomimetic-like Agent [EPC]. Area: Neuroscience.

marketed Sympathomimetic-like Agent [EPC] D(2) dopamine receptor Neuroscience Live · refreshed every 30 min

Target snapshot

Provigil (modafinil) — Nuvo Pharms. Provigil works by increasing the activity of certain neurotransmitters in the brain, such as dopamine, to help regulate sleep-wake cycles.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Provigil TARGET	modafinil	Nuvo Pharms	marketed	Sympathomimetic-like Agent [EPC]	D(2) dopamine receptor	1998-01-01
Pramipexole (Mirapex)	Pramipexole (Mirapex)	Massachusetts General Hospital	marketed	Dopamine agonist	D2 dopamine receptor, D3 dopamine receptor
Adjunctive asenapine	Adjunctive asenapine	Lori Davis, MD	marketed	Atypical antipsychotic	D2 dopamine receptor, 5-HT2A serotonin receptor
LYBALVI	LYBALVI	Alkermes, Inc.	marketed	Atypical antipsychotic with opioid antagonist	D2 dopamine receptor, 5-HT7 serotonin receptor, mu-opioid receptor
Aripiprazole Augmentation	Aripiprazole Augmentation	Centre for Addiction and Mental Health	marketed	Atypical antipsychotic / dopamine partial agonist	D2 dopamine receptor, 5-HT1A serotonin receptor
Quetiapine and Topiramate	Quetiapine and Topiramate	University of Cincinnati	marketed	Atypical antipsychotic + anticonvulsant mood stabilizer combination	D2 dopamine receptor, 5-HT2A serotonin receptor (quetiapine); voltage-gated sodium channels, carbonic anhydrase (topiramate)
Continuous Subcutaneous Lisuride Infusion	Continuous Subcutaneous Lisuride Infusion	Axxonis Pharma AG	phase 3	Dopamine agonist	D1 and D2 dopamine receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Sympathomimetic-like Agent [EPC] class)

Nuvo Pharms · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Provigil — Competitive Intelligence Brief. https://druglandscape.com/ci/modafinil. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab